| Literature DB >> 15283899 |
Kara Smigel Croker1, Anne Ryan, Thuy Morzenti, Lynn Cave, Tamara Maze-Gallman, Leslie Ford.
Abstract
The Prostate Cancer Prevention Trial was the first clinical trial to show that a direct intervention (5 mg of finasteride daily for 7 years) could reduce a man's risk of developing prostate cancer. Initial results also suggested that men taking finasteride had an increased risk of developing what appeared to be higher-grade disease (Gleason score 7-10). The National Cancer Institute has a congressional mandate to communicate health information to the public and has established methods to reach the public directly and to reach information intermediaries in the media, professional societies, and advocacy groups. The groundbreaking yet complicated results of the Prostate Cancer Prevention Trial were widely disseminated by National Cancer Institute using the social marketing and public-relations strategies and tactics detailed here. Copyright 2004 Elsevier Inc.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15283899 DOI: 10.1016/j.urolonc.2004.04.015
Source DB: PubMed Journal: Urol Oncol ISSN: 1078-1439 Impact factor: 3.498